Skip to main
ACHV
ACHV logo

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences Inc. shows a promising outlook due to the validated mechanism and robust clinical efficacy of its key product, cytisinicline, which addresses a significant market need for smoking and vaping cessation therapies. The company's recent sales figures indicate a potential market size of $1.6 billion, with further growth anticipated from the expansion of vaping-related labeling. Additionally, the favorable safety profile and flexible dosing options of cytisinicline are expected to enhance patient adherence and broaden its adoption, contributing to long-term growth and share appreciation.

Bears say

Achieve Life Sciences Inc. faces a negative outlook primarily due to concerns regarding the commercial viability of cytisinicline despite its demonstrated efficacy in clinical trials, as slow adoption rates are anticipated in the cigarette smoking indication. The company's projections have been adjusted downward, with peak market penetration in the vaping segment reduced from 10% to 8%, reflecting skepticism about market acceptance and adoption. Additionally, the need for competitive differentiation is heightened by observations that other treatments like bupropion may be encountering similar outcomes regarding patient interest in smoking cessation, further complicating Achieve's market positioning.

ACHV has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Buy based on their latest research and market trends.

According to 2 analysts, ACHV has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.